---

---

SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

---

Amendment No. 1
on
FORM 10-Q/A

|/x/ |  | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|--- |  | ---------------------------------------------------------------------------------------

For the period ended September 30, 2000

Commission file number 80-19878

---

OPTION CARE, INC.(Exact name of registrant as specified in its charter)

Delaware(State of incorporation)

36-3791193(IRS Employer Identification No.)100 Corporate North, Suite 212
Bannockburn, Illinois(Address of principal executive offices)

60015(zip code)


(847) 615-1690(Registrant's telephone number, including area code)

---

Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 Yes /x/  No / /

Indicate
the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class

Issued and Outstanding
as of October 31, 2000Common Stock.01 par value

12,032,405


---

---

---

EXPLANATORY NOTE

In consultation with its professional accounting advisors, the Company is filing this Amendment No. 1 on Form 10-Q/A for the quarter
ended September 30, 2000 to amend the Company's financial statements and the related Management's Discussion and Analysis of Financial Condition and Results of Operations to reflect the
reclassification of certain tax benefits from employee stock option exercises, equal to $255,000 or $0.02 of earnings per diluted share, from income tax expense to additional paid-in
capital.

---

INDEX

OPTION CARE, INC. & SUBSIDIARIES

|PART I     |  | FINANCIAL INFORMATION                                                                                                                        
|---------- |  | ---------------------------------------------------------------------------------------------------------------------------------------------
|Item 1.    |  | Financial Statements (Unaudited)                                                                                                             
|           |  | Condensed consolidated balance sheetsSeptember 30, 2000 and December 31, 1999                                                               
|           |  | Condensed consolidated statements of operationsThree months ended September 30, 2000 and 1999; Nine months ended September 30, 2000 and 1999
|           |  | Condensed consolidated statements of cash flowsNine months ended September 30, 2000 and 1999                                                
|           |  | Notes to condensed consolidated financial statementsSeptember 30, 2000                                                                      
|Item 2.    |  | Management's Discussion and Analysis of Financial Condition and Results of Operations                                                        
|Item 3.    |  | Quantitative and Qualitative Disclosures of Market Risk                                                                                      
|PART II    |  | OTHER INFORMATION                                                                                                                            
|Item 1.    |  | Legal Proceedings                                                                                                                            
|Item 2.    |  | Changes in Securities and Use of Proceeds                                                                                                    
|Item 3.    |  | Defaults Upon Senior Securities                                                                                                              
|Item 4.    |  | Submission of Matters to a Vote of Security Holders                                                                                          
|Item 5.    |  | Other Information                                                                                                                            
|Item 6(a). |  | Exhibits                                                                                                                                     
|Item 6(b). |  | Reports on Form 8-K                                                                                                                          

---



OPTION CARE INC. AND SUBSIDIARIES        CONDENSED CONSOLIDATED BALANCE SHEETS        (In thousands, except per share amounts)

PART I.  FINANCIAL INFORMATION

Item 1.  Financial Statements

|                                           |                                                                                                                                                  | September 30, 2000 |        | December 31, 1999
|------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------ | ------ | -----------------
|
|Assets                                     |                                                                                                                                                  |                    |        |                  
|Current assets:                            |                                                                                                                                                  |                    |        |                  
|                                           | Cash and cash equivalents                                                                                                                        |                    | $      |                 
|                                           | Accounts receivable, net                                                                                                                         |                    |        | 26,860           
|                                           | Inventories, net                                                                                                                                 |                    |        | 1,821            
|                                           | Other current assets                                                                                                                             |                    |        | 4,156            
|                                           |                                                                                                                                                  |                    |        |                  
|Total current assets                       |                                                                                                                                                  |                    | 32,837 |                  
|Equipment and other fixed assets, net      |                                                                                                                                                  |                    | 4,342  |                  
|Goodwill, net                              |                                                                                                                                                  |                    | 25,104 |                  
|Other assets                               |                                                                                                                                                  |                    | 1,420  |                  
|                                           |                                                                                                                                                  |                    |        |                  
|Total assets                               |                                                                                                                                                  | $                  | 63,703 |                  
|                                           |                                                                                                                                                  |                    |        |                  
|Liabilities and Stockholders' equity       |                                                                                                                                                  |                    |        |                  
|Current liabilities:                       |                                                                                                                                                  |                    |        |                  
|                                           | Cash overdraft                                                                                                                                   |                    | $      | 1,225            
|                                           | Trade accounts payable                                                                                                                           |                    |        | 4,460            
|                                           | Other current liabilities                                                                                                                        |                    |        | 5,924            
|                                           |                                                                                                                                                  |                    |        |                  
|Total current liabilities                  |                                                                                                                                                  |                    | 11,609 |                  
|Long-term debt, excluding current portion  |                                                                                                                                                  |                    | 14,651 |                  
|Other liabilities                          |                                                                                                                                                  |                    | 803    |                  
|Minority interest                          |                                                                                                                                                  |                    | 447    |                  
|                                           |                                                                                                                                                  |                    |        |                  
|Total liabilities                          |                                                                                                                                                  |                    | 27,510 |                  
|Stockholders' equity:                      |                                                                                                                                                  |                    |        |                  
|                                           | Common stock, $.01 par value per share, 30,000 shares authorized, 12,005 and 11,493 shares issued and outstanding in 2000 and 1999, respectively |                    |        | 120              
|                                           | Common stock to be issued, 197 and 235 shares in 2000 and1999, respectively                                                                      |                    |        | 758              
|                                           | Other stockholders' equity                                                                                                                       |                    |        | 35,315           
|                                           |                                                                                                                                                  |                    |        |                  
|Total stockholders' equity                 |                                                                                                                                                  |                    | 36,193 |                  
|                                           |                                                                                                                                                  |                    |        |                  
|Total liabilities and stockholders' equity |                                                                                                                                                  | $                  | 63,703 |                  
|                                           |                                                                                                                                                  |                    |        |                  

See notes to condensed consolidated financial statements.

2

---

OPTION CARE, INC. AND SUBSIDIARIES        CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS        (Unaudited)  (In thousands, except per share amounts)

|                                               |         | Three Months Ended
September 30, |        | Nine Months Ended
September 30, |  
|---------------------------------------------- | ------- | -------------------------------- | ------ | ------------------------------- | -
|
|Revenue                                        |         | $                                | 35,265 |                                 | $
|Cost of revenue                                |         |                                  | 21,620 |                                 |  
|                                               |         |                                  |        |                                 |  
|Gross profit                                   |         |                                  | 13,645 |                                 |  
|Selling, general and administrative expenses   |         |                                  | 9,292  |                                 |  
|Provision for doubtful accounts                |         |                                  | 580    |                                 |  
|Amortization of goodwill                       |         |                                  | 161    |                                 |  
|                                               |         |                                  |        |                                 |  
|Total operating expenses                       |         |                                  | 10,033 |                                 |  
|                                               |         |                                  |        |                                 |  
|Operating income                               |         |                                  | 3,612  |                                 |  
|Interest expense                               |         |                                  | (267   | )                               |  
|Other expense, net                             |         |                                  | (86    | )                               |  
|                                               |         |                                  |        |                                 |  
|Income before income taxes                     |         |                                  | 3,259  |                                 |  
|Income tax provision                           |         |                                  | 1,258  |                                 |  
|                                               |         |                                  |        |                                 |  
|Net income                                     |         | $                                | 2,001  |                                 | $
|                                               |         |                                  |        |                                 |  
|Net income per common share:                   |         |                                  |        |                                 |  
|                                               | Basic   |                                  | $      | 0.17                            |  
|                                               |         |                                  |        |                                 |  
|                                               | Diluted |                                  | $      | 0.16                            |  
|                                               |         |                                  |        |                                 |  
|Shares used in computing net income per share: |         |                                  |        |                                 |  
|                                               | Basic   |                                  |        | 12,060                          |  
|                                               |         |                                  |        |                                 |  
|                                               | Diluted |                                  |        | 12,469                          |  
|                                               |         |                                  |        |                                 |  

See notes to condensed consolidated financial statements.

3

---



OPTION CARE, INC. AND SUBSIDIARIES        CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS        (Unaudited)  (In thousands)

|                                                                                  |  | Nine Months Ended
September 30, |       
|--------------------------------------------------------------------------------- |  | ------------------------------- | ------
|
|Cash flows from operating activities:                                             |  |                                 |       
|Net income                                                                        |  | $                               | 5,330 
|Adjustments to reconcile net income to net cash provided by operating activities: |  |                                 |       
|Depreciation and amortization                                                     |  |                                 | 2,217 
|Provision for doubtful accounts                                                   |  |                                 | 1,923 
|Other                                                                             |  |                                 | 255   
|Accounts receivable                                                               |  |                                 | (4,254
|Inventory                                                                         |  |                                 | 1,890 
|Accounts payable                                                                  |  |                                 | (1,301
|Accrued expenses                                                                  |  |                                 | (934  
|Accrued wages                                                                     |  |                                 | (323  
|Income taxes payable                                                              |  |                                 | (580  
|Change in other current assets and current liabilities                            |  |                                 | 383   
|                                                                                  |  |                                 |       
|Net cash provided by operating activities                                         |  |                                 | 4,606 
|                                                                                  |  |                                 |       
|Cash flows from investing activities:                                             |  |                                 |       
|Other assets, net                                                                 |  |                                 | (507  
|Purchases of equipment and other, net                                             |  |                                 | (756  
|Payments for acquisitions, net of cash acquired                                   |  |                                 | (6,777
|                                                                                  |  |                                 |       
|Net cash used in investing activities                                             |  |                                 | (8,040
|                                                                                  |  |                                 |       
|Cash flows from financing activities:                                             |  |                                 |       
|(Decrease) increase of cash overdraft                                             |  |                                 | (3,067
|Retirement of previous debt facility                                              |  |                                 |      
|Net borrowing on revolving credit agreement                                       |  |                                 | 2,466 
|Net borrowing on acquisition line                                                 |  |                                 | 3,800 
|Payments on capital leases                                                        |  |                                 | (112  
|Payments of other long-term debt                                                  |  |                                 | (19   
|Proceeds from issuance of stock                                                   |  |                                 | 366   
|                                                                                  |  |                                 |       
|Net cash provided by (used in) financing activities                               |  |                                 | 3,434 
|                                                                                  |  |                                 |       
|Net decrease in cash and cash equivalents                                         |  |                                 |      
|Cash and cash equivalents, beginning of period                                    |  |                                 |      
|                                                                                  |  |                                 |       
|Cash and cash equivalents, end of period                                          |  | $                               |      
|                                                                                  |  |                                 |       

See notes to condensed consolidated financial statements.

4

---



OPTION CARE, INC. AND SUBSIDIARIES        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS        (Unaudited)  (In thousands, except per share amounts)
September 30, 2000

1.  Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for
interim financial information and with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and footnotes required by generally accepted
accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been
included. Operating results for the three- and nine-month periods ended September 30, 2000 are not necessarily indicative of the results that may be expected for the year ending
December 31, 2000.

The
balance sheet at December 31, 1999 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by
generally accepted accounting principles for complete financial statements.

For
further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year
ended December 31, 1999.

2.  Reclassifications

Certain amounts in the condensed consolidated financial statements have been reclassified to conform to the current year presentation.

3.  Long-Term Debt

On February 5, 1999, the Company entered into a $25,000 Loan and Security Agreement ("Loan Agreement") with a bank that replaced the Company's former
credit facility. The Loan Agreement provides for borrowings up to $25,000 and requires the Company to meet certain financial covenants including, but not limited to: fixed charge coverage ratio, debt
ratio and limitation on annual capital expenditures. The Loan Agreement allowed the Company, among other things, to meet working capital needs and to retire in its entirety the Company's former
facility. Under the Loan Agreement, the Company is subject to an early termination fee if the loan is terminated prior to its natural expiration of February 2002. The Company paid a facility
fee of $185 at the time of signing the Loan Agreement. The Loan Agreement prohibits the Company from declaring any cash dividends on its common stock. The Company may elect interest rates ranging from
various LIBOR periods plus a 2.125% margin to the bank's reference rate. The average interest rate for the third quarter of 2000 on outstanding borrowings under the facility was 8.9%.

Effective
November 1, 1999, borrowing availability under the facility is related to a percentage of the Company's net outstanding account receivable and inventory balances,
less certain ineligible amounts, as defined in the Loan Agreement. The facility is secured by the assets of the Company. Overall borrowings allowable under the Loan Agreement are limited to the lessor
of $25,000 or the total allowable collateral base.

On
June 30, 2000, the Company amended the Loan Agreement by expanding the lending group to include another bank and increasing the total amount available under the Loan
Agreement to $40,000. The additional $15,000 portion represents an acquisition line ("Acquisition Line") that can be drawn

5

---

upon by the Company for a period of one year, expiring on June 30, 2001. The amount, if any, not drawn upon prior to the expiration date shall expire and the Company will not have any ability
to borrow such amounts. All borrowings under the Acquisition Line must be for approved acquisitions, as defined. The Company paid a facility fee of $150 at the time of signing the Acquisition Line. As
of September 30, 2000, the Company had $3,800 outstanding under the Acquisition Line. The average interest rate for the third quarter of 2000 on outstanding borrowings under the Acquisition
Line was 9.7%.

4.  Earnings Per Share Data

The following table sets forth the computation of basic and diluted earnings per share for the periods indicated:

|                                                                        |  | Three Months Ended
September 30, |        | Nine Months Ended
September 30,
|----------------------------------------------------------------------- |  | -------------------------------- | ------ | -------------------------------
|
|Basic:                                                                  |  |                                  |        |                                
|Net income                                                              |  | $                                | 2,001  |                                
|                                                                        |  |                                  |        |                                
|Average shares outstanding                                              |  |                                  | 12,060 |                                
|Basic earnings per share                                                |  | $                                | 0.17   |                                
|                                                                        |  |                                  |        |                                
|Diluted:                                                                |  |                                  |        |                                
|Net income                                                              |  | $                                | 2,001  |                                
|                                                                        |  |                                  |        |                                
|Average shares outstanding                                              |  |                                  | 12,060 |                                
|Net effect of dilutive stock optionsbased on the treasury stock method |  |                                  | 409    |                                
|                                                                        |  |                                  |        |                                
|Total diluted shares                                                    |  |                                  | 12,469 |                                
|                                                                        |  |                                  |        |                                
|Diluted earnings per share                                              |  | $                                | 0.16   |                                
|                                                                        |  |                                  |        |                                

5.  Operating Segments

In January 2000, the Company realigned its operations and developed two identifiable operating segments: infusion and services; and specialty pharmacy.
Infusion and services is comprised of revenue from infusion therapy, product sales and royalty fees. Specialty pharmacy includes revenue from the

6

---

distribution of specialty pharmaceuticals. Inter-segment sales are recorded at cost and there is no inter-company profit or loss on inter-segment sales or transfers.

|                                |  | Three months ended
September 30, 2000 |  | Three months ended
September 30, 1999
|------------------------------- |  | ------------------------------------- |  | -------------------------------------
|
|Net sales to external customers |  | 25,086                                |  | 10,179                               
|Inter-segment net sales         |  |                                      |  | 2,151                                
|Gross profit                    |  | 12,238                                |  | 1,407                                
|Operating income                |  | 2,856                                 |  | 756                                  
|Total assets                    |  | 59,505                                |  | 4,198                                

|                                |  | Nine months ended
September 30, 2000 |  | Nine months ended
September 30, 1999
|------------------------------- |  | ------------------------------------ |  | ------------------------------------
|
|Net sales to external customers |  | 72,963                               |  | 28,220                              
|Inter-segment net sales         |  |                                     |  | 5,548                               
|Gross profit                    |  | 35,639                               |  | 3,957                               
|Operating income                |  | 7,714                                |  | 1,879                               

In
the third quarter of 2000, the Company reclassified Human Growth Hormone operations from the Company's Michigan location from infusion and services segment into the specialty
pharmacy segment. The revenue reclassified was $1,980 and $1,098 for the first quarter of 2000 and 1999, respectively and $2,473 and $904 for the second quarter of 2000 and 1999, respectively.
Reclassifications for gross profit and operating profit related to this revenue had no material impact.

6.  Acquisitions

During the quarter ended September 30, 2000, the Company purchased certain assets of the franchise offices located in Hemet, California and Fairfax,
Virginia. The aggregate purchase price paid at closing for these transactions was $3,735, which was paid with funds borrowed under the Company's Acquisition Line. In addition, the Company entered into
agreements with the sellers of each acquired business, whereby additional contingent purchase price may be paid out upon the business meeting predetermined financial metrics over the next one to three
year periods. Payments to be made under
these agreements, if any, would be made up to 45 days after the anniversary date of each acquisition. Any amounts to be paid out under these agreements will be recorded as additional goodwill
in the period in which the amount due is certain.

The
purchase method of accounting was used to record the acquisitions and $1,224 of goodwill was recorded. The accompanying condensed financial statements include the results of
operations of all acquired businesses from the date of acquisition. The acquisitions would not have a material impact on operating results on a pro-forma basis.

7

---

Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31,
1999. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this Quarterly Report on
Form 10-Q and other materials filed or to be filed by the Company with the Securities and Exchange Commission (as well as information included in oral statements or other written
statements made or to be made by the Company) contains statements that are or will be forward-looking, such as statements relating to acquisitions and other business developments activities, future
capital expenditures and the effects of future regulation and competition. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated
results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by, or on behalf of, the Company. These risks and uncertainties include, but
are not limited to, uncertainties affecting businesses of the Company and its franchisees relating to acquisitions and divestitures (including continuing obligations with respect to completed
transactions), sales and renewals of franchises, government and regulatory policies (including federal, state and local efforts to reform the delivery of and payment for healthcare services), general
economic conditions (including economic conditions affecting the healthcare industry in particular), the pricing and availability of equipment and services, technological developments and changes in
the competitive environment in which the Company operates.

Discussion of Results of Operations for the Three Month and Nine Month periods ended September 30, 2000 (in thousands, expect per share amounts)

REVENUE

|                         |                  | Three Months Ended
September 30, |        | Nine Months Ended
September 30, |      
|------------------------ | ---------------- | -------------------------------- | ------ | ------------------------------- | -----
|
|Infusion and services:   |                  |                                  |        |                                 |      
|                         | Infusion therapy |                                  | $      | 22,019                          |      
|                         | Royalty fees     |                                  |        | 2,434                           |      
|                         | Product sales    |                                  |        | 633                             |      
|                         |                  |                                  |        |                                 |      
|Infusion and services    |                  | $                                | 25,086 |                                 | 71.1 
|Specialty pharmacy       |                  |                                  | 10,179 |                                 | 28.9 
|                         |                  |                                  |        |                                 |      
|Total revenue            |                  | $                                | 35,265 |                                 | 100.0
|                         |                  |                                  |        |                                 |      
|Growth over prior period |                  | $                                | 5,068  |                                 | 16.8 
|                         |                  |                                  |        |                                 |      

Total
revenue for the three months ended September 30, 2000 was $35,265, which was $5,068 or 16.8% higher than the $30,197 reported for the three months ended
September 30, 1999. The revenue for the three months ended September 30, 2000 represents the seventh consecutive quarter of revenue growth and represents an all time high of revenue for
a quarter in the Company's 21 years of existence. The three-month period ended September 30, 2000 also represents the third straight quarter of over 10% growth in revenue for the
Company.

The
infusion and services segment is comprised of infusion therapy revenue, royalty fee revenue and product sales. The fluctuations for each are described as follows:

Infusion
therapy revenue during the third quarter of 2000 increased $2,551, or 13.1%, to $22,019 from the $19,468 of revenue from the third quarter of 1999, due primarily to a
same-store (defined as Option Care locations owned for more than a year) revenue increase of 12.1% and $400 of new revenue realized from the Company's acquisitions made during the quarter.
Year-to-date, infusion

8

---

therapy revenue in 2000 increased $5,537, or 9.5%, over the prior year period, primarily as a result of a 10.2% increase in same store sales. Infusion therapy represented 62.4% and 63.3% of revenue
for the Company for the quarter and year-to-date, respectively, through September 30, 2000 as compared to 64.5% and 65.9% for the comparable periods of 1999. Infusion
therapy revenue as a percentage of total revenue has declined due primarily to the rapid growth from the Company's specialty pharmacy revenue.

Royalty
fee revenue for the third quarter of 2000 of $2,434 represented an increase of $103, or 4.4%, over the third quarter of 1999. The increase is due to increased revenue by the
Company's franchise network. Overall network revenue was negatively impacted by a decline in office locations as the Company has aggressively begun to close out small non-productive
offices from its franchise system and has acquired two franchise locations. As of September 30, 2000, the total number of offices in the Company's franchise network has declined to 104 from 117
at December 31, 1999.

For
the nine months ended September 30, 2000, royalty fee revenue of $7,080, increased $851, or 13.7%, reflecting the increase of revenue by the Company's franchise network.
Royalty fee revenue was 7.0% of total revenue, for the nine month periods ended September 30, 2000 and 1999.

Product
sales for the third quarter of 2000 of $633 represented a decrease of $72, or 10.2%, from the third quarter of 1999 sales of $705. The decline was primarily due to reduced
shipments of the Company's MBI 5.0 software. For the nine months ended September 30, 2000, product sales was $1,868, a decrease of $177, or 8.7%, from the $2,045 of product sales in the
comparable period of 1999.

Specialty
pharmacy revenue, consisting of the Company's OptionMed division, was $10,179 for the third quarter of 2000, an increase of $2,486, or 32.3% over the $7,693 of revenue in
the third quarter of 1999. The increase for the third quarter 2000 is primarily due to increased orders made through managed care contracts at the Company's southern Florida location as well as
increased orders of human growth hormone at the Company's Michigan location. For the nine months ended September 30, 2000, specialty pharmacy revenue was $28,220, an increase of $6,174, or
28.0%, from 1999's year-to-date revenue of $22,046. Specialty pharmacy revenue as a percentage of total revenue increased to 28.9% of total revenue for the three months ended
September 30, 2000, up from 25.5% for the comparable period in 1999. Year-to-date through September 30, 2000, specialty pharmacy revenue as a percentage of total
revenue was 27.9%, an increase over the 24.8% from the corresponding period in 1999.

GROSS PROFIT

|                         |                  | Three Months Ended
September 30, |        | Nine Months Ended
September 30, |     
|------------------------ | ---------------- | -------------------------------- | ------ | ------------------------------- | ----
|
|Infusion and services:   |                  |                                  |        |                                 |     
|                         | Infusion therapy |                                  | $      | 9,254                           |     
|                         | Royalty fees     |                                  |        | 2,434                           |     
|                         | Product sales    |                                  |        | 550                             |     
|                         |                  |                                  |        |                                 |     
|Infusion and services    |                  | $                                | 12,238 |                                 | 48.8
|Specialty pharmacy       |                  |                                  | 1,407  |                                 | 13.8
|                         |                  |                                  |        |                                 |     
|Gross Profit             |                  | $                                | 13,645 |                                 | 38.7
|                         |                  |                                  |        |                                 |     
|Growth over prior period |                  |                                  | 7.6    | %                               |     
|                         |                  |                                  |        |                                 |     

Gross
profit margin for the third quarter of 2000 was 38.7%, a decline of 3.3% from the gross profit margin of 42.0% in the third quarter of 1999. The gross profit margin realized in
the third

9

---

quarter of 2000 for infusion therapy was 42.0%, representing a decline of 1.2% from the 43.2% margin realized in the third quarter of 1999. The decline was due in part to a shift in the mix of
infusion therapies made during the quarter. Year-to-date 2000 gross margin as compared to year-to-date 1999 gross margin for infusion therapy declined
for the same reasons as the quarterly margin decline. Royalty revenue has no direct cost of goods associated with it, rather costs incurred to derive this type of revenue are captured as part of
selling, general and administrative expenses. Gross margin for product sales has increased slightly for both the three-month and nine month periods ended September 30, 2000 as compared to
corresponding periods in 1999.

Specialty
pharmacy gross margin in third quarter of 2000 declined to 13.8% from 17.7% realized in the third quarter of 1999 due to the higher level of sales during the quarter of
human growth hormone (HGH) which has a lower margin than other specialty pharmaceuticals. Currently, the Company sells approximately 35 different specialty pharmaceuticals products through the
OptionMed division and the margin for HGH is one of the lowest margin providers. Year-to-date 2000 gross margin as compared to year-to-date 1999 gross
margin for specialty pharmacy declined for the same reasons as the quarterly margin decline.

OPERATING EXPENSES

|                             |  | Three Months Ended
September 30, |        | Nine Months Ended
September 30, |     
|---------------------------- |  | -------------------------------- | ------ | ------------------------------- | ----
|
|S,G & A expenses             |  | $                                | 9,292  |                                 | 26.3
|Provision for doubtful accts |  |                                  | 580    |                                 | 1.6 
|Amortization of goodwill     |  |                                  | 161    |                                 | 0.6 
|                             |  |                                  |        |                                 |     
|Total operating expenses     |  | $                                | 10,033 |                                 | 28.5
|                             |  |                                  |        |                                 |     
|Increase over prior period   |  | $                                | 1      |                                 | 0.0 
|                             |  |                                  |        |                                 |     

Total
operating expenses for the three months ended September 30, 2000 were $10,033, in line with the $10,032 for the three months ended September 30, 1999. Selling,
general and administrative expenses (S,G & A) declined by $20 for the quarter from $9,312 realized in the third quarter of 1999 to $9,292 for the third quarter of 2000. S,G & A
expenses remained in line with the prior years quarters amount despite the recent hiring of new executives to help manage the Company's growth, including a new Chief Information Officer, Senior Vice
President of Business Development and Senior Vice President of Network Management.

In
addition, the growth percentage of S,G & A expenses was less than the revenue growth realized by the Company resulting in a percentage of S,G & A to revenue decline
quarter over quarter, from 30.8% in the third quarter of 1999 to 26.3% in the third quarter of 2000. The decline represents the third consecutive quarter in 2000 that the percentage of S,G & A
expenses to revenue for the quarter has declined over the percentage realized for the prior year quarter. The continuing decline in the percentage of operating expenses to revenue reflects continued
sustained productivity improvements and the favorable impact on operating expenses of the change in revenue mix to increased specialty pharmacy revenue.

The
provision for bad debt declined as a percentage of revenue to 1.6% for the third quarter of 2000 from 1.9% for the third quarter of 1999. The decline is primarily attributable to
the change in the

10

---

Company's revenue mix to more specialty pharmacy revenue. Historically, specialty pharmacy revenue has resulted in a better collection ratio. For the nine months ended September 30, 2000, the
provision for bad debt as a percentage of revenue of 1.9% has also declined from the 2.2% in the comparable period in 1999, reflecting the change in the Company's revenue mix.

Amortization
of goodwill increased slightly from the third quarter of 1999's amount of $138 to the third quarter of 2000's amount of $161, due in part to the Company's new
acquisitions and to contingent payments made under certain of the Company's prior acquisition agreements. Year-to-date, amortization of goodwill increased from $407 for 1999 to
2000's amount of $475 for the same reasons as mentioned for the growth for the quarter.

INTEREST EXPENSE

Interest expense increased by $28, or 11.7%, to $267 for the three months ended September 30, 2000 from $239 for the corresponding period in the prior
year, due primarily to the additional borrowing incurred to fund the Company's acquisitions made in the third quarter of 2000. Year-to-date, interest expense of $715 has
declined $95, or 11.7%, from $810, as debt levels throughout 2000, prior to the third quarter, have remained at levels lower in 2000 than in 1999.

INCOME TAXES

The effective income tax rate for the third quarter of 2000 was 38.6%, which represents a decline from the third quarter of 1999's effective income tax rate of
42.4%. Such decline was due to the deductibility of certain items during the third quarter of 2000. Year-to-date, the effective income tax rate of 38.0% for 2000 also
represents a decline from the effective income tax rate of 42.2% for 1999, due to the same reason.

EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION (EBITDA)

|                              |  | Three Months Ended
September 30, |       | Nine Months Ended
September 30, |  
|----------------------------- |  | -------------------------------- | ----- | ------------------------------- | -
|
|Net income                    |  | $                                | 2,001 |                                 | $
|Interest expense              |  |                                  | 267   |                                 |  
|Income taxes                  |  |                                  | 1,258 |                                 |  
|Depreciation and amortization |  |                                  | 589   |                                 |  
|Goodwill amortization         |  |                                  | 161   |                                 |  
|                              |  |                                  |       |                                 |  
|EBITDA                        |  | $                                | 4,276 |                                 | $
|                              |  |                                  |       |                                 |  
|Growth over prior period      |  | $                                | 1,060 |                                 |  
|                              |  |                                  |       |                                 |  

EBITDA
of $4,276 for the third quarter of 2000 represents an increase of $1,060, or 33.0% over the third quarter of 1999. Year-to-date, EBITDA for the nine
months ended September 30, 2000 of $11,532, represents an increase of $2,756 or 31.4%.

EARNINGS PER SHARE

As a result of the above noted increases, the Company reported earnings per diluted share of $0.16 for the third quarter of 2000, an increase of $0.05, or
45.5%, over the $0.11 earnings per diluted share for the same period in 1999. Earnings per diluted share also increased by $0.02, or 14.3%, over the $0.14 earning per diluted share realized in the
second quarter of 2000. For the nine months ended

11

---

September 30, 2000, earnings per diluted share of $0.43 represents an increase of $0.16, or 59.3%, from $0.27 for the comparable period in 1999.

In
addition, diluted shares during the third quarter of 2000 increased from 12,034 at the end of the third quarter 1999 to 12,469 at September 30, 2000, an increase of 435, or
3.6%, due to the exercise of options, the issuance of shares as part of contingency payments made for acquisitions made in 1996 and 1997 and the effect of the market price of the Company's stock. The
year-to-date 2000 diluted shares of 12,473 increased as compared to year-to-date 1999 of 11,922, an increase of 551, or 4.6%.

Liquidity and Capital Resources

CASH AND CASH EQUIVALENTS

As of September 30, 2000, the Company had no cash and cash equivalents, in line with the amount of cash and cash equivalents at December 31,
1999. The Company has instituted a policy of using excess cash balances, if any, to retire outstanding debt under its revolver agreement.

NET CASH FLOWS

Net cash flow provided by operations for the nine months ended September 30, 2000 was $4,606, a decline of $2,772 from the $7,378 provided by operations
during the same period in 1999. The decline was primarily due to an increase in accounts receivable, increased income tax payments paid during 2000 due to the Company's increased profitability,
reductions of several liabilities during the first nine months of 2000, increased compensation expenses and payments made to renew the Company's insurance program.

Net
cash flow used in investing activities for the months ended September 30, 2000 was $8,040, an increase of $5,362 over the $2,678 used in the first nine months of 1999. The
increase was due to payments made for new acquisitions and due to the increases in and the timing of deferred purchase price payments for acquisitions made in prior years.

Net
cash flow provided by financing activities was $3,434 for the first nine months of 2000, an increase of $11,799 over the use of $8,365 from the comparable period in 1999. The
increase was primarily the result of the effect of the repayment by the Company of the former credit facility in the first quarter of 1999.

LONG TERM DEBT

|                                                     |  | 9/30/00 |        | % of total |       | 12/31/99 |   | % of total |  | 9/30/99 |   | % of total |       
|---------------------------------------------------- |  | ------- | ------ | ---------- | ----- | -------- | - | ---------- |  | ------- | - | ---------- | ------
|Revolving credit agreement                           |  | $       | 10,782 |            | 72.9  | %        | $ | 8,317      |  | 96.8    | % | $          | 10,942
|Acquisition line                                     |  |         | 3,800  |            | 25.7  | %        |   |           |  | 0.0     | % |            |      
|Capital leases                                       |  |         | 87     |            | 0.6   | %        |   | 165        |  | 1.9     | % |            | 185   
|Other long term debt                                 |  |         | 118    |            | 0.8   | %        |   | 108        |  | 1.3     | % |            | 158   
|                                                     |  |         |        |            |       |          |   |            |  |         |   |            |       
|Total debt outstanding                               |  | $       | 14,787 |            | 100.0 | %        | $ | 8,590      |  | 100.0   | % | $          | 11,285
|                                                     |  |         |        |            |       |          |   |            |  |         |   |            |       
|Increase (decrease) from prior period                |  |         |        |            |       |          | $ | 6,197      |  | 41.9    | % | $          | 3,502 
|                                                     |  |         |        |            |       |          |   |            |  |         |   |            |       
|Increase (decrease) from prior (without Acquisition) |  |         |        |            |       |          | $ | 2,397      |  | 27.9    | % | $          | (298  
|                                                     |  |         |        |            |       |          |   |            |  |         |   |            |       

Total
debt outstanding of $14,787 at September 30, 2000 increased in the third quarter by $3,502, or 31.0%, over the amount of debt held at September 30, 1999. The
increase was largely the result of borrowings made by the Company in the third quarter of 2000 to fund acquisitions made during the

12

---

quarter. Debt outstanding at September 30, 2000 of $14,787 represents an increase of $6,197, or 72.1%, over the amount of debt outstanding at December 31, 1999. A total of $3,800 of the
increase is due to the new acquisitions and the remainder is due in part to the decline in the Company's cash overdraft, representing net outstanding checks, over this same period. The decline in cash
overdraft account is a function of timing and is driven by the vendors that the Company pays and how quickly they deposit the checks paid to them. Debt under the Company's revolver agreement was at a
lower amount at year-end 1999 than it normally would have been due to the high cash overdraft level. The Company does not anticipate the same occurrence to happen at year-end
2000.

Management
believes that cash flow from operations and availability under the Loan Agreement will be sufficient to meet the cash needs of the business for the immediate future. In the
event that additional capital is required, management cannot assure that such capital can be obtained on terms acceptable to the Company.

GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill and other intangible assets, net, at September 30, 2000 was $26,287, an increase of $4,220 over the $22,067 at December 31, 1999. The
increase is primarily due to payments made under certain of the Company's purchase agreements for acquisitions made in 1997 and 1996 as well as from the recognition of goodwill from the Company's
acquisitions made during the third quarter of 2000. Payments made under agreements for acquisitions made prior to 2000 were for additional consideration to former owners upon the satisfaction of
certain contingencies and represented additional purchase price for these acquisitions. Amounts recorded from acquisitions made during the third quarter of 2000 were recorded at the fair market value
of the tangible and intangible assets at the time they were acquired were less than the amount paid for these assets.

Total
net goodwill and other intangible assets at September 30, 2000, increased as a percentage of total assets from 38.3% at December 31, 1999 to 41.3% at
September 30, 2000, due mainly to the additional payments and the acquisitions made during the quarter. Total net goodwill and other intangible assets
declined as a percentage of stockholders' equity from 75.3% at December 31, 1999 to 72.6% at September 30, 2000, due mainly to the increase in stockholders' equity realized from the net
income recognized for 2000.

Acquisitions
made in the current quarter, as well as in prior years, have resulted in the recognition of a significant amount of goodwill on the Company's financial statements.
Goodwill was recorded as the fair market value of the tangible and intangible assets at the time they were acquired were less than the amount paid for these assets. The Company has determined that the
goodwill recorded as a result of acquisitions made in prior years will benefit the Company for a period of not less than 40 years and, as a result, are amortizing the goodwill over this period.
For acquisitions made in 2000, the Company is amortizing goodwill over a 20-year period. There can be no assurance that the Company will realize the full value of the goodwill recorded.
The Company, on an on-going basis, evaluates whether events and circumstances indicate that all or some of the carrying value of goodwill is no longer recoverable and will take a charge to
earnings for the amount so determined in the period that the goodwill has been determined to be no longer recoverable.

In
addition, the Company's current growth strategy may involve the acquisition of additional companies and these acquisitions may result in the recognition of additional amounts of
goodwill. The amortization of this goodwill could have a negative impact on future earnings. Also, as part of an acquisition, the Company may be required to allocate certain portions of the purchase
price to the value of non-compete agreements, patient records and contracts that are acquired. The value of any amounts allocated to these items may be amortized over a period much shorter
than the 20 years that goodwill will be amortized over. As a result, the Company's future earnings may be negatively impacted by the amount of this amortization.

13

---

REGULATORY AND OTHER DEVELOPMENTS

Recent government investigations into how the average wholesale price ("AWP") for certain pharmaceuticals are determined could result in reduced pricing and
margins on certain drugs that the Company currently supplies to patients. Various federal and state government agencies have been investigating whether the AWP of many drugs is an appropriate or
accurate measure of market prices from which government payors determine how much they reimburse for the drug. Many government payors pay the Company, either directly or indirectly, for some of the
drugs based on that drug's AWP, or at a percentage off AWP. In addition, the Company has also contracted with a number of private payors to sell at AWP or at a percentage discount off AWP.

AWP
for most drugs is compiled and published by a private company, First DataBank, Inc. It has been reported that there, currently, are several lawsuits pending against
manufacturers of certain drugs. These government investigations and lawsuits involve allegations that manufacturers have misrepresented the actual selling price of certain drugs to First DataBank.
First DataBank has announced that it will base AWP on market prices certified by the manufacturer. First DataBank has published a Market Price Survey that reduces the AWP significantly for a number of
the products the Company currently supplies to patients. The Company cannot predict the eventual results of these investigations, and the changes made in AWP by First DataBank.

If
the reduced average wholesale prices published by First DataBank for the drugs that the Company currently provides to patients are ultimately adopted as the standard by which the
Company is reimbursed by government payors or private payors, it could have a material adverse effect on the Company's business, financial condition, and results of operation, including reducing the
pricing and margins on certain of the Company's products. For the nine months ended September 30, 2000, less than approximately 20% of the Company's total revenue were generated from
governmental agencies.

In
addition, there are currently various proposals under development to enact healthcare reform on a national, state and local level. It is not possible at this time to predict the
cash flow impact, if any, which any such changes may have on providers of home healthcare services and on the Company's locations.

14

---



Item 3.  Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.

|                     |  | OPTION CARE, INC.
|-------------------- |  | -----------------
|Date: March 12, 2001 |  | By:              

15

---

Exhibit Index

|Exhibit
Number |  |                                                                                                                                                                                                                                                                
|-------------- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|3.1            |  | Certificate of Incorporation of the Registrant, together with Certificate of Amendment thereto filed February 18, 1992. Filed as Exhibit 3(a) to the Company's Registration Statement (No. 33-45836) dated
April 15, 1992 and incorporated by reference herein.
|3.2            |  | Certificate of Amendment to Certificate of Incorporation of the Registrant filed March 25, 1992. Filed as Exhibit 3(c) to the Company's Registration Statement (No. 33-45836) dated April 15, 1992 and incorporated by reference
herein.                       
|3.3            |  | Restated By-laws of the Registrant dated June 1, 1994. Filed as Exhibit 10.5 to the Company's Annual Report on Form 10-K for the year ending December 31, 1994 and incorporated by reference herein.                                                           
|27             |  | Financial Data Schedule*                                                                                                                                                                                                                                       
|*              |  | previously filed                                                                                                                                                                                                                                               

---

QuickLinks